A new study sheds light on why promising cancer treatments can produce dramatically different results across patients.

A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how ...

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

Cancer’s strongest gene switches push DNA into damaging overdrive, creating repeated breaks and repairs that may fuel tumor ...

Carcinoma ex pleomorphic adenoma (CXPA) is a rare type of salivary gland cancer. Surgery and radiation therapy are the most common treatment options. CXPA develops from a noncancerous tumor called ...